Advanced CSF testing for glioblastoma: how it works, what results mean, and how it may help diagnose GBM/rGBM without surgery or biopsy.
Advanced CSF testing for glioblastoma: how it works, what results mean, and how it may help diagnose GBM/rGBM without surgery or biopsy.
Discover the Exvade Monorail Device, an FDA Breakthrough technology for real-time glioblastoma tracking. Learn about the clinical trial.
The European Commission has approved VORANIGO (vorasidenib) for IDH-mutant gliomas, representing a significant advancement in targeted brain cancer therapy.
Explore a Phase 2 clinical trial for Primary Central Nervous System Lymphoma (PCNSL). Learn about eligibility and enrollment details at EndBrainCancer.org.
Learn the results of a national survey of PCNSL patients and care partners.
Discover brain cancer treatment options for 2025. Learn about clinical trials, personalized medicine, and patient advocacy from the End Brain Cancer Initiative.
The EndBrainCancer Initiative seeks a volunteer CFO to provide financial leadership and strategic oversight. Apply to support the mission and make a difference.
The FDA has approved VORANIGO, the first targeted therapy for Grade 2 IDH-mutant glioma, marking a significant advancement in brain cancer treatment.
Explore the SonALAsense SDT-201 trial, a non-invasive sonodynamic therapy for pediatric DIPG, a rare and aggressive brain cancer.
Discover how the 3D Predict™ Glioma test uses living cells to identify the most effective treatments for brain cancer.
New dedicated website for the Prospect primary central nervous system lymphoma study.
Imvax is conducting a clinical trial to assess the safety and efficacy of IGV-001, an autologous biologic-device combination product in GBM patients.
